All In Biotech

Free tool

FAERS Monitor: Omvoh

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761279 or its brand name (Omvoh, Mirikizumab-Mrkz). Reports on generic versions are filed under their own applications.

Reports

903

Serious

489

54% of reports

Hospitalization

176

Death reported

26

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • colitis ulcerative155
  • injection site pain89
  • drug ineffective81
  • diarrhoea37
  • haematochezia35
  • arthralgia30
  • incorrect dose administered29
  • headache27
  • rash27
  • frequent bowel movements25
  • off label use24
  • maternal exposure during pregnancy23
  • abdominal pain22
  • pyrexia19
  • dizziness17

Reports by year received

View as table
YearReports
202322
2024312
2025318
2026251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,256 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
colitis ulcerativeSignal15581.070.212,158
frequent bowel movementsSignal2521.614.7470
haematocheziaSignal3514.810.7437
injection site painSignal896.85.5437
maternal exposure during pregnancySignal236.04.092
incorrect dose administeredSignal293.02.136
abdominal painSignal222.21.513
arthralgia301.71.28
rash271.41.03
drug ineffective811.41.211
diarrhoea371.31.03
pyrexia191.30.81
headache271.00.70
dizziness170.80.51
off label use240.60.45

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.